Comparative Pharmacology
Head-to-head clinical analysis: OPANA ER versus ROXYBOND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPANA ER versus ROXYBOND.
OPANA ER vs ROXYBOND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
None Documented
None Documented
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic